Angela M. Carter

Angela M. Carter

Auto-generated profile, based on publicly available information

Angela M. Carter

Department of Surgery, University of Alabama at Birmingham

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Theranostics
Verified
Journal Article
Open access
JMJonathan O. Martinez
Jonathan O. Martinez
Roberto MolinaroRoberto Molinaro
Roberto Molinaro
KHKelly A. Hartman
Kelly A. Hartman
CBChristian Boada
Christian Boada
RSRoman Sukhovershin
Roman Sukhovershin
ETEnnio Tasciotti
Ennio Tasciotti
Activation of the vascular endothelium is characterized by increased expression of vascular adhesion molecules and chemokines. This activation occurs early in the progression of several diseases and triggers the recruitment of leukocytes. Inspired by the tropism of leukocytes, we investigated leukocyte-based biomimetic nanoparticles (i.e., leukosomes) as a novel theranostic platform for inflammatory diseases.

1 April 2013 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
FMFrank Medina
Frank Medina
ACAngela M. Carter
Angela M. Carter
ODOlugbenga Dada
Olugbenga Dada
SGStephen Gutowski
Stephen Gutowski
JHJana Hadas
Jana Hadas
PSPaul C. Sternweis
Paul C. Sternweis
The monomeric Rho GTPases are essential for cellular regulation including cell architecture and movement. A direct mechanism for hormonal regulation of the RhoA-type GTPases is their modulation by the G12 and G13 proteins via RH (RGS homology) containing RhoGEFs. In addition to the interaction of the G protein α subunits with the RH domain, activated RhoA also binds to the pleckstrin homology (PH) domain of PDZRhoGEF. The latter interaction is now extended to all seven members of the homologous Lbc family of RhoGEFs which includes the RH-RhoGEFs. This is evinced by direct measurements of binding or through effects on selected signaling pathways in cells. Overexpression of these PH domains alone can block RhoA-dependent signaling in cells to various extents. Whereas activated RhoA does not modulate the intrinsic activity of the RhoGEFs, activated RhoA associated with phospholipid vesicles can facilitate increased activity of soluble RhoGEFs on vesicle-delimited substrate (RhoA-GDP). This demonstrates feasibility of the hypothesis that binding of activated RhoA to the PH domains acts as a positive feedback mechanism. This is supported by cellular studies in which mutation of this binding site on PH strongly attenuates the stimulation of RhoA observed by overexpression of five of the RhoGEF DH-PH domains. This mutation is even more dramatic in the context of full-length p115RhoGEF. The utilization of this mechanism by multiple RhoGEFs suggests that this regulatory paradigm may be a common feature in the broader family of RhoGEFs.

1 January 2007 in Advances in Protein Chemistry
Verified
Book Chapter
Closed access
PSPaul C. Sternweis
Paul C. Sternweis
ACAngela M. Carter
Angela M. Carter
ZCZhe Chen
Zhe Chen
SDShahab M. Danesh
Shahab M. Danesh
YHYing‐Fan Hsiung
Ying‐Fan Hsiung
WSWilliam D. Singer
William D. Singer

20 July 2020 in Cancer Gene Therapy
Verified
Journal Article
Closed access
PDF file
YSYingnan Si
Yingnan Si
SKSeulhee Kim
Seulhee Kim
JOJianfa Ou
Jianfa Ou
YLYun Lu
Yun Lu
PEPatrick Ernst
Patrick Ernst
MLMargaret Liu
Margaret Liu

20 July 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
ACAngela M. Carter
Angela M. Carter
CTChunfeng Tan
Chunfeng Tan
KPKarine Pozo
Karine Pozo
RTRahul Telange
Rahul Telange
Roberto MolinaroRoberto Molinaro
Roberto Molinaro
JBJames A. Bibb
James A. Bibb
Significance: This study validates a path toward personalized medicine that utilizes a survey of the effective signaling state of tumors via posttranslational modification analysis as a diagnostic alternative to direct examination of genetic mutations. Here, this approach is utilized to identify biomarkers for Cdk5-driven tumors. The same approach could be adapted to identify markers of other tumor drivers. As the number of cancer types in which Cdk5 is implicated is rising and as drugs with the potential to selectively target Cdk5 are moved toward the clinic, the translational potential of this diagnostic–therapeutic coupled system will be broad.

18 May 2021 in eLife
Verified
Journal Article
Open access
JAJenny I Aguilar
Jenny I Aguilar
MCMary Hongying Cheng
Mary Hongying Cheng
JFJosep Font
Josep Font
ASAlexandra C Schwartz
Alexandra C Schwartz
KLKaitlyn Ledwitch
Kaitlyn Ledwitch
AGAurelio Galli
Aurelio Galli
Parkinson disease (PD) is a progressive, neurodegenerative disorder affecting over 6.1 million people worldwide. Although the cause of PD remains unclear, studies of highly penetrant mutations identified in early-onset familial parkinsonism have contributed to our understanding of the molecular mechanisms underlying disease pathology. Dopamine (DA) transporter (DAT) deficiency syndrome (DTDS) is a distinct type of infantile parkinsonism-dystonia that shares key clinical features with PD, including motor deficits (progressive bradykinesia, tremor, hypomimia) and altered DA neurotransmission. Here, we define structural, functional, and behavioral consequences of a Cys substitution at R445 in human DAT (hDAT R445C), identified in a patient with DTDS. We found that this R445 substitution disrupts a phylogenetically conserved intracellular (IC) network of interactions that compromise the hDAT IC gate. This is demonstrated by both Rosetta molecular modeling and fine-grained simulations using hDAT R445C, as well as EPR analysis and X-ray crystallography of the bacterial homolog leucine transporter. Notably, the disruption of this IC network of interactions supported a channel-like intermediate of hDAT and compromised hDAT function. We demonstrate that Drosophila melanogaster expressing hDAT R445C show impaired hDAT activity, which is associated with DA dysfunction in isolated brains and with abnormal behaviors monitored at high-speed time resolution. We show that hDAT R445C Drosophila exhibit motor deficits, lack of motor coordination (i.e. flight coordination) and phenotypic heterogeneity in these behaviors that is typically associated with DTDS and PD. These behaviors are linked with altered dopaminergic signaling stemming from loss of DA neurons and decreased DA availability. We rescued flight coordination with chloroquine, a lysosomal inhibitor that enhanced DAT expression in a heterologous expression system. Together, these studies shed some light on how a DTDS-linked DAT mutation underlies DA dysfunction and, possibly, clinical phenotypes shared by DTDS and PD.